EA201491622A1 - Биспецифические антитела против baff и ил-17 - Google Patents

Биспецифические антитела против baff и ил-17

Info

Publication number
EA201491622A1
EA201491622A1 EA201491622A EA201491622A EA201491622A1 EA 201491622 A1 EA201491622 A1 EA 201491622A1 EA 201491622 A EA201491622 A EA 201491622A EA 201491622 A EA201491622 A EA 201491622A EA 201491622 A1 EA201491622 A1 EA 201491622A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bispecific antibodies
baff
antibodies against
against baff
sle
Prior art date
Application number
EA201491622A
Other languages
English (en)
Other versions
EA029185B1 (ru
Inventor
Барретт Аллан
Роберт Ян Беншоп
Цзижун Лу
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201491622A1 publication Critical patent/EA201491622A1/ru
Publication of EA029185B1 publication Critical patent/EA029185B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Предложены биспецифические антитела, которые специфически связываются с фактором активации В-клеток из семейства ФНО (BAFF) и интерлейкином-17А (ИЛ-17), которые характеризуются высокой аффинностью и высокими нейтрализующими свойствами как в отношении BAFF, так и в отношении ИЛ-17. Ожидается, что биспецифические антитела согласно настоящему изобретению можно будет применять в лечении волчаночного нефрита (ВН), системной красной волчанки (СКВ), ревматоидного артрита (РА), псориаза (Пс), анкилозирующего спондилоартрита (АС), псориатического артрита (ПА), первичного синдрома Шегрена (пСШ) или множественной миеломы (ММ).
EA201491622A 2012-04-20 2013-04-16 Биспецифические антитела против baff и ил-17 EA029185B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636302P 2012-04-20 2012-04-20
US201361768747P 2013-02-25 2013-02-25
PCT/US2013/036677 WO2013158577A1 (en) 2012-04-20 2013-04-16 Anti-baff-anti-il-17 bispecific antibodies

Publications (2)

Publication Number Publication Date
EA201491622A1 true EA201491622A1 (ru) 2015-01-30
EA029185B1 EA029185B1 (ru) 2018-02-28

Family

ID=48539373

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491622A EA029185B1 (ru) 2012-04-20 2013-04-16 Биспецифические антитела против baff и ил-17

Country Status (40)

Country Link
US (2) US9359448B2 (ru)
EP (2) EP2838920B1 (ru)
JP (1) JP6216772B2 (ru)
KR (1) KR101673735B1 (ru)
CN (1) CN104220455B (ru)
AP (1) AP2014008002A0 (ru)
AR (1) AR090626A1 (ru)
AU (1) AU2013249546B2 (ru)
BR (1) BR112014025649A2 (ru)
CA (1) CA2869148C (ru)
CL (1) CL2014002616A1 (ru)
CO (1) CO7160039A2 (ru)
CR (1) CR20140466A (ru)
CY (1) CY1118824T1 (ru)
DK (1) DK2838920T3 (ru)
DO (1) DOP2014000234A (ru)
EA (1) EA029185B1 (ru)
EC (1) ECSP14023405A (ru)
ES (2) ES2621917T3 (ru)
GT (1) GT201400217A (ru)
HK (1) HK1201862A1 (ru)
HR (1) HRP20170468T1 (ru)
HU (1) HUE032153T2 (ru)
IL (1) IL234965B (ru)
IN (1) IN2014MN01876A (ru)
LT (1) LT2838920T (ru)
ME (1) ME02596B (ru)
MX (1) MX367460B (ru)
MY (1) MY173282A (ru)
NZ (1) NZ630865A (ru)
PE (1) PE20142147A1 (ru)
PH (1) PH12014502333A1 (ru)
PL (1) PL2838920T3 (ru)
PT (1) PT2838920T (ru)
RS (1) RS55729B1 (ru)
SG (1) SG11201406726PA (ru)
SI (1) SI2838920T1 (ru)
TW (1) TWI585103B (ru)
WO (1) WO2013158577A1 (ru)
ZA (1) ZA201407272B (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2012149227A (ru) 2010-05-20 2014-06-27 Аблинкс Нв Биологические материалы, относящиеся к her3
UA117218C2 (uk) 2011-05-05 2018-07-10 Мерк Патент Гмбх Поліпептид, спрямований проти il-17a, il-17f та/або il17-a/f
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos
TW201444867A (zh) * 2013-03-08 2014-12-01 Lilly Co Eli 抗ｔｎｆ－抗ｉｌ－１７雙特異性抗體
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
CA2929846C (en) * 2013-11-19 2020-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
WO2016039801A1 (en) 2014-01-31 2016-03-17 Boehringer Ingelheim International Gmbh Novel anti-baff antibodies
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
TW202144411A (zh) * 2015-07-23 2021-12-01 德商包林格因蓋爾漢國際股份有限公司 靶向il-23a與b細胞活化因子(baff)之化合物及其用途
CN105061596B (zh) * 2015-08-05 2019-01-29 江苏诺迈博生物医药科技有限公司 人b淋巴细胞刺激因子的单克隆抗体及其应用
US20200385478A1 (en) * 2018-01-05 2020-12-10 Biograph 55, Inc. Compositions and methods for cancer immunotherapy
CN117529506A (zh) * 2021-06-11 2024-02-06 海南先声药业有限公司 抗人il-17抗体和taci的双功能融合蛋白分子

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995009917A1 (en) 1993-10-07 1995-04-13 The Regents Of The University Of California Genetically engineered bispecific tetravalent antibodies
AR035119A1 (es) * 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
RU2515108C2 (ru) * 2005-08-19 2014-05-10 Эббви Инк Иммуноглобулин с двойными вариабельными доменами и его применения
KR101158959B1 (ko) 2005-12-13 2012-07-09 일라이 릴리 앤드 캄파니 항-ｉｌ-17 항체
US20110293629A1 (en) * 2010-05-14 2011-12-01 Bastid Jeremy Methods of Treating and/or Preventing Cell Proliferation Disorders with IL-17 Antagonists
AR090626A1 (es) * 2012-04-20 2014-11-26 Lilly Co Eli Anticuerpos anti-baff-anti-il-17 biespecificos

Also Published As

Publication number Publication date
CA2869148C (en) 2017-06-20
BR112014025649A2 (pt) 2017-07-04
PH12014502333B1 (en) 2014-12-22
ES2621917T3 (es) 2017-07-05
AU2013249546A1 (en) 2014-09-25
LT2838920T (lt) 2017-05-25
SG11201406726PA (en) 2014-11-27
JP6216772B2 (ja) 2017-10-18
EP2838920B1 (en) 2017-02-01
ES2789474T3 (es) 2020-10-26
MX367460B (es) 2019-08-22
MY173282A (en) 2020-01-10
KR20140135830A (ko) 2014-11-26
WO2013158577A1 (en) 2013-10-24
PH12014502333A1 (en) 2014-12-22
KR101673735B1 (ko) 2016-11-07
AR090626A1 (es) 2014-11-26
JP2015514423A (ja) 2015-05-21
US9708402B2 (en) 2017-07-18
EP2838920A1 (en) 2015-02-25
HRP20170468T1 (hr) 2017-06-02
RS55729B1 (sr) 2017-07-31
GT201400217A (es) 2015-06-02
DOP2014000234A (es) 2014-11-30
TW201402607A (zh) 2014-01-16
EP3192809A1 (en) 2017-07-19
TWI585103B (zh) 2017-06-01
SI2838920T1 (sl) 2017-03-31
CR20140466A (es) 2014-11-13
EA029185B1 (ru) 2018-02-28
NZ630865A (en) 2016-02-26
US20160251430A1 (en) 2016-09-01
US20130280256A1 (en) 2013-10-24
CN104220455A (zh) 2014-12-17
AU2013249546B2 (en) 2017-10-26
CA2869148A1 (en) 2013-10-24
DK2838920T3 (en) 2017-04-18
CY1118824T1 (el) 2018-01-10
PL2838920T3 (pl) 2017-07-31
IL234965B (en) 2018-04-30
PE20142147A1 (es) 2014-12-13
PT2838920T (pt) 2017-05-03
CO7160039A2 (es) 2015-01-15
US9359448B2 (en) 2016-06-07
MX2014012692A (es) 2015-01-22
HUE032153T2 (en) 2017-09-28
EP3192809B1 (en) 2020-04-15
HK1201862A1 (en) 2015-09-11
IN2014MN01876A (ru) 2015-07-03
CL2014002616A1 (es) 2015-01-30
AP2014008002A0 (en) 2014-10-31
ME02596B (me) 2017-06-20
ZA201407272B (en) 2016-11-30
ECSP14023405A (es) 2015-09-30
CN104220455B (zh) 2017-04-26

Similar Documents

Publication Publication Date Title
EA201491622A1 (ru) Биспецифические антитела против baff и ил-17
MX2015011957A (es) Anticuerpos biespecificos anti-tnf-anti-il-17.
EA201890565A1 (ru) Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз
EP4311558A3 (en) Antibodies that bind il-23
UA117575C2 (uk) Антитіло, яке специфічно зв'язується з il-17a та його застосування
EA201791422A1 (ru) Фармацевтические продукты и устойчивые жидкие композиции антител к il-17
NZ703607A (en) Heteroaromatic compounds as bruton’s tyrosine kinase (btk) inhibitors
EA201690325A1 (ru) БИСПЕЦИФИЧЕСКИЕ МОНОВАЛЕНТНЫЕ Fc-ДИАТЕЛА, КОТОРЫЕ СПОСОБНЫ СВЯЗЫВАТЬ CD32B И CD79b, И ИХ ПРИМЕНЕНИЯ
TR201909531T4 (tr) Anti-il-17 anti̇korlari kullanilarak anki̇lozan spondi̇li̇t tedavi̇ etme yöntemleri̇
EP4036240A3 (en) Transduction buffer
EA201490195A1 (ru) Не содержащие аргинина композиции слитого fc-полипептида и способы их применения
EA201791734A1 (ru) Способ лечения воспалительных заболеваний
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
EA201491471A1 (ru) Состав, содержащий антитело против ил-17
MX2016006101A (es) Agente ligante de la il-17a y usos del mismo.
EA202193002A2 (ru) Соединение, нацеленное на ил-23a и фно-альфа, и его применение
TN2014000413A1 (en) Anti-baff-anti-il-17 bispecific antibodies
TH1401006266A (th) แอนติ-baff-แอนติ-il-17ไบสเปซิฟิกแอนติบอดี
UA113080C2 (xx) Біспецифічне антитіло, яке специфічно зв'язується з il17 та baff
WO2014113431A3 (en) Methods and compositions for targeting immunoglobulins
EA202090128A3 (ru) Антитела против антигена 2 дендритных клеток крови и их применение

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM